Quick Answer
Regencell Bioscience Holdings Ltd reported Operating Income of -$3.77 million for fiscal year 2025.
Regencell Bioscience Holdings Ltd Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$3.77M | +20.4% |
| 2024 | -$4.74M | +24.5% |
| 2023 | -$6.27M | +17.6% |
| 2022 | -$7.62M | -451.5% |
| 2021 | -$1.38M | -70.0% |
| 2020 | -$812.4K | -107.8% |
| 2019 | -$391.0K | — |
- Regencell Bioscience Holdings Ltd showed an increase of +20.4% in Operating Income compared to the prior fiscal year.
- Over the 2019–2025 period, Regencell Bioscience Holdings Ltd’s operating income has declined by 864.2% (from -$391.0 thousand to -$3.77 million).
- The most recent figure is from Regencell Bioscience Holdings Ltd’s fiscal year 2025 report (Form 20-F), filed with the SEC on October 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: